Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

ACADIA Pharma

Alector Inc

Amarin Corporation Plc

Avadel Pharma

Biogen

Epizyme

G1 Therapeutics

MacroGenics

Syros Pharmaceuticals

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.

Major Biopharma Catalysts on the December FDA Calendar

Bausch Health Companies is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Bausch Health Companies

Teva Pharmaceutical

Zynerba Pharmaceuticals

Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.

Generic Drugmakers Gain as Price-Fixing Probe Nears an End

Bausch Health Companies (NYSE: BHC), formerly Valeant Pharmaceuticals, has seen its share price rally more than 50% over the last two months. There were 2 main reasons for this:
- The company’s share price sank 90% from its peak level in 2015 on account of legal scrutiny in price rigging.

Why Did Bausch Health Companies’ [BHC] Stock Jump 50% In 2 Months?

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at Stifel 2019 Healthcare Conference (Transcript)

The growing number of bankruptcies among biotech companies should send shudders through investors.

Teva, Bausch Could Be Next to File for Bankruptcy

As of late, it has definitely been a great time to be an investor Bausch Health.

Will Bausch Health Continue to Surge Higher?

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bausch (BHC) Moves to Buy: Rationale Behind the Upgrade

Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.

Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance

McDonald's

Under Armour

Berkshire Hathaway, McDonald's, Under Armour and Bausch Health were our top stock trades from Monday. Here's a look at the charts.

4 Top Stock Trades for Tuesday: MCD, UAA, Berkshire

Bausch Health Companies Inc. (BHC) CEO Joseph Papa on Q3 2019 Results - Earnings Call Transcript

Bausch Health Companies Inc (NYSE: BHC) reported Monday ahead of the market open with better-than-expected third-quarter revenue and higher non-GAAP earnings.

Bausch Analyst Sees Challenging Setup For Next Leg Of Recovery Story

Bausch Health Cos. Inc. BHC, +4.35% said Monday it had a met loss of $49 million, or 14 cents a share, in the third quarter, after a loss of $350 million, or $1.00 a share, in the year-earlier period.

Bausch Health loss narrows in latest quarter

Bausch Health Companies (NYSE: BHC) announces its next round of earnings this Monday, November 4.

Q3 Earnings Outlook For Bausch Health Companies

Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.

Implied Volatility Surging for Bausch Health (BHC) Stock Options

Three years after Citron Research called Valeant the “pharmaceutical Enron,” the firm said Tuesday that it’s time to give Valeant successor Bausch Health Companies Inc (NYSE: BHC) the credit it is due for its rebranding and turnaround efforts.

Citron Calls Bausch Health — Formerly Valeant — The 'Textbook Turnaround'

Axsome Therapeutics

Change Healthcare Inc

HealthEquity

La Jolla Pharmaceutical

This year, for the first time in many years, active managers are outperforming index funds, and that should be a loud wake-up call to passive investors.

SunTrust Has 5 Sizzling Health Care High-Conviction Picks for Q4

Novartis

Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.

Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

Aurora Cannabis

AMTD International Inc

A big industry announcement took one of these stocks lower.

Why TD Ameritrade, Bausch Health, and Aurora Cannabis Slumped Today

A lawsuit over the company's top-selling drug caused investors to worry.

Why Bausch Health Companies Stock Sank Today

Bausch Health Cos. Inc. BHC, +0.69% said Tuesday it is filing a lawsuit against Novartis AG unit Sandoz NVS, -0.57% for the infringement of patents protecting its Xifaxan 550 mg tablets, a treatment for irritable bowel syndrome.

Bausch files suit against Novartis unit Sandoz for infringing patents on Xifaxan 550 mg tablets

Bausch Health has strong revenue growth ahead with Trulance, its B+L division, and its Salix unit.

4 More Reasons Bausch Health Is A Good Buy

AbbVie

Alexion Pharma

Cigna

CVS Health

Intercept Pharma

Johnson & Johnson

Eli Lilly

Pfizer

PRA Health Sciences

Eli Lilly, Alexion and AbbVie are just some of the top healthcare stocks to buy here, now that disappointing news has driven them to cheap prices.

10 Healthcare Stocks to Buy Despite the Headlines

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Down 4.7% Since Last Earnings Report?

Bausch Health Companies Inc. BHC, -0.79% said Tuesday it is planning to reduce its debt by about $200 million by repaying senior secured term loans and redeeming senior notes using cash flow from operations.

Bausch to pay reduce its debt by about $200 million by repaying loans, redeeming bonds

News for Bausch Health Companies Inc Stock (BHC)